The PCV13 vaccine makes it easier for the immune system to attack S. pneumoniae and produce antibodies by linking the polysaccharide capsule layer to proteins. Exposure to neonatal antibiotics reduces ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Prevenar 13 is a mixture of the outer sugar coating (polysaccharide ... child have ever had an allergic reaction to pneumococcal or diphtheria vaccines, or any of the ingredients listed at ...

polysaccharide-based jab Pneumovax 23. Sanofi's new challenger is billed as a "next-generation" pneumococcal conjugate vaccine that, according to the company, is the first candidate with more than ...

Pneumococcal 20-valent conjugate ... receiving 13-valent pneumococcal conjugate vaccine (Prevnar 13) followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses ...

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

Already facing one rival to its blockbuster pneumococcal ... combines polysaccharide and protein antigens – joined with a biotin-rhizavidin bond – that can stimulate both B cell (antibody ...

The levels of antibodies that correlate with protection against pneumococcal ... either meningococcal polysaccharide serogroup A or placebo. The 6- and 12-valent vaccines achieved a protective ...

No serious adverse events were considered to be related to the study vaccines. Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative ...

NA: Not applicable; PCV-7: 7-valent pneumococcal conjugate vaccine; PCV-13: 13-valent pneumococcal conjugate vaccine; PPV23: 23-valent pneumococcal polysaccharide vaccine.